Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive BCI product entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices [1][2] - Clinical practices for BCIs in China are accelerating, with several hospitals initiating clinical applications and trials, positioning China as the second country globally to enter the clinical trial phase for invasive BCIs [3] Industry Developments - The BCI industry is expected to achieve key technological breakthroughs by 2027, establishing an advanced technical, industrial, and standard system, with a goal of nurturing globally influential companies by 2030 [2] - The BCI market is projected to grow significantly, with estimates indicating a market size of approximately $2.62 billion in 2024, reaching $2.94 billion by 2025, and potentially growing to $12.4 billion by 2034 [4] Clinical and Commercial Progress - Major hospitals in China are launching BCI clinical applications, with initiatives such as the first BCI outpatient clinic in Central China and the establishment of specialized clinical wards for BCI technology [3] - The development of BCI technology is seen as a beacon of hope for over 3 billion people suffering from neurological disorders globally [3] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Nanjing Panda Electronics is also engaged in BCI technology development, focusing on multimodal human-computer interaction systems [5]
国内首个脑机接口进入审批绿通，商业化应用落地有望加速(附概念股)